Ultragenyx Pharmaceutical(RARE) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update First quarter total revenue of $139 million, Crysvita® revenue of$103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between$640 million to $670 million, Crysvita revenue of$460 million to $480 million, and Dojolvi revenue of$90 million to $100 million UX111, an investigational treatment for ...